Sample size
SECONDARY
Sample size calculations were made for the placebo-controlled period and no power calculations were made for the extension period. Based on simulations, an estimated 280 patients per treatment arm (eptinezumab 100 mg, 300 mg, and placebo) provided ≥ 90% power for the primary endpoint and ≥ 68% power for the individual key secondary endpoints [